Alzheimer's research and help, in plain English.

Medical Xpress ·November 2, 2026

Parkinson's disease (PD) is a neurodegenerative condition that causes the progressive loss of dopamine-producing neurons in a brain region called the substantia nigra.

• Other Dementias
• Treatments
• Risk Factors

ScienceDaily ·November 2, 2026

A major 24-year study involving more than 8,200 adults suggests that excess body weight may accelerate brain aging, leading to faster declines in memory, concentration, and decision-making skills. …

Alzheimer's News Today ·November 2, 2026

Today, landmarks around the world will be lit up teal as advocates globally work to raise awareness — throughout this entire month — about Alzheimer’s disease. …

Medical Xpress ·November 2, 2026

A defining feature of Alzheimer's disease is the abnormal, sustained accumulation of protein aggregates such as tau inside brain cells, which disrupts the cells' normal functions. …

Medical Xpress ·November 2, 2026

A study of for-profit hospices acquired by private equity firms found that Medicare spending rose by 5.9% per hospice stay after acquisition, compared with similar for-profit hospices that weren't acquired. …

• Policy
• Health Equity

69/100 ✓ Peer-reviewed 2026-10-29

The PROMPPT trial will assess whether review by trained clinical pharmacists working in general practices can support safe opioid reduction without compromising pain management and quality of life. (+1 more on the study page)

• Clinical Trials
• Care Services
• Policy

74/100 ✓ Peer-reviewed 2026-10-16

Midlife p-tau181 was associated with faster 11-year memory decline beginning 20 years later in the ARIC cohort, which underscores a potentially long prodromal phase of cognitive decline that could precede dementia onset. (+4 more on the study page)

• Biomarkers

70/100 ✓ Peer-reviewed 2026-10-13

Nine proteins (amyloid-beta 42 (Aβ42), beta-secretase 1 (BACE1), glial fibrillary acidic protein (GFAP), pTau181, pTau231, pTau217, t0tal tau (MAPT), neurofilament light (NfL) and acetylcholinesterase (AChE)) robustly differed between carriers and non-carriers cross-sectionally. (+4 more on the study page)

• Biomarkers
• Genetics

68/100 ✓ Peer-reviewed 2026-10-05

This study analyzed 871 eyes from 439 participants (230 APOE ε4 noncarriers and 209 carriers). (+4 more on the study page)

• Brain Scans
• Early Stage
• Genetics

73/100 ✓ Peer-reviewed 2026-10

Females with MCI exhibited greater baseline GMV than males primarily in the thalamus, caudate, cerebellum, postcentral gyrus, and middle cingulate gyrus, with no differences at the AD stage. (+2 more on the study page)

• Early Stage